\_Άi1995NΘ~j
1995N
Sato,
Y. Activation of latent TGF-b at the vascular wall. Roles of endothelial
cells and mural pericytes or smooth muscle cells. J. Atheroscler. Thromb.2:24-29, 1995.
Hori, K., Zhang, Q.H., Li, H.C., and Saito, S.
Variation of growth rate of a rat tumour during a light-dark cycle: correlation
with circadian fluctuations in tumour blood flow. Br. J. Cancer.
71:1163-1168, 1995.
1996N
Hori,
K., Zhang, Q.-H., Li, H.-C., Saito, S., and Sato, Y. Timing of cancer
chemotherapy based on circadian variation in tumor blood flow. Int. J. Cancer 65:360-364, 1996.
Ono,
M., Kawahara, N., Goto, D., Wakabayashi, Y., Ushiro, S., Yoshida, S., Izumi,
H., Kuwana, M., and Sato, Y. Inhibition of tumor growth and neovascularization
by an anti-gastric ulcer agent, irsogladine. Cancer Res. 56:1512-1516, 1996.
Abe,
H., Abe, M., Tanaka, K., Iwasaka, C., and Sato, Y. Simultaneous bindings of uPA
and latnt TGF-b for the
activation of latent TGF-b in homotypic smooth muscle cells. Tohoku J. Exp. Med. 179:23-34,
1996.
Ono,
M., Izumi, H., Yoshida, S., Goto, D., Jimi, S., Kawahara, N., Shono, T.,
Ushiro, S., Ryuto, M., Kohno, K., Sato, Y., and Kuwano, M. Angiogenesis as a new
target for cancer treatment. Cancer
Chemother. Pharmacol. 38 (Suppl.):S78-S82, 1996.
Hori,
K., Saito, S., and Sato, Y. Daily changes in tumor blood flow after cancer
chemotherapy. Microcirculation Annual
1996:215-216, 1996.
Iwasaka,
C., Tanaka, K., Abe, M., and Sato, Y. Ets-1 regulates angiogenesis by inducing
the expression of urokinase-type plasminogen activator and matrix
metalloproteinase-1 and the migration of vascular endothelial cells. J. Cell. Physiol. 169:522-531, 1996.
1997N
Hori,
K., Li, H.-C., Saito, S., and Sato, Y. Increased growth and incidence of lymph
node metastases due to the angiogenesis inhibitor AGM-1470. Br. J. Cancer 75:1730-1734, 1997.
Sato,
Y., Iwasaka, C., Tanaka, K.,
1998N
Abe,
M., Oda, N., and Sato, Y. Cell-associated activation of latent transforming
growth factor-b by calpain. J. Cell. Physiol. 174:186-193, 1998.
Takahashi,
H., Abe, M., Sugawara, T., Tanaka, K., Saito, Y., Fujimura, S., Shibuya, M.,
and Sato, Y. Clotrimazole, an imidazole antimycotic, is a potent inhibitor of
angiogenesis. Jpn. J. Cancer, Res.
89:445-451, 1998.
Tanaka,
K., Oda, N., Iwasaka, C., Abe, M., and Sato, Y. Induction of Ets-1 in
endothelial cells during re-endothelialization after denuding injury. J. Cell. Physiol. 176:235-244, 1998.
Sato,
Y. Role of a transcription factor ETS-1 in angiogenesis. Connective Tissue 30:291-295, 1998.
Sato,
Y. Transcription factor ETS-1 as a molecular target for angiogenesis inhibition.
Human Cell 11:207-214, 1998.
1999N
Oda,
N., Abe, M., and Sato, Y. ETS-1 converts endothelial cells to the angiogenic
phenotype by inducing the expression of matrix metalloproteinases and integrin b3. J. Cell. Physiol. 178:121-132, 1999.
Okamoto,
O., Fujiwara, S., Abe, M., and Sato, Y. Dermatopontin interacts with
transforming growth factor b and enhances its biological activity. Biochem. J. 337:537-541, 1999.
Nishimura,
M., Miki, T., Yashima, R., Sato, Y., and Seino S. Angiopoietin-3, a novel member
of the angiopoietin family. FEBS Lett.
448:254-256, 1999.
Kanno,
S., Oda, N., Abe, M., Saito, S., Hori, K., Handa, Y., Tabayashi, K., and Sato,
Y. Establishment of a simple and practical procedure applicable to therapeutic
angiogenesis. Circulation 99:2682-2687,
1999.
Tanaka,
K., Abe, M., and Sato, Y. Roles of ERK1/2 and p38 MAP kinase in the signal
transduction of bFGF in endothelial cells during angiogenesis. Jpn. J. Cancer Res. 90:647-654, 1999.
Nihei,
Y., Suga, Y., Morinaga, Y., Ohishi, K., Okano, A., Ohsumi, K., Hatanaka, T.,
Nakagawa, R., Tsuji, T., Akiyama, Y., Saito, S., Hori, K., Sato, Y., and Tsuruo,
T. A Novel Combretastatin A-4 derivative, AC-7700, shows marked antitumor
activity against advanced solid tumors and orthotopically transplanted tumors. Jpn. J. Cancer Res. 90: 1016-1025,
1999.
Hori,
K., Saito, S., Nihei, Y., Suzuki, M., and Sato, Y. Antitumor effects due to
irreversible stoppage of tumor tissue blood flow: evaluation of a novel
combretastatin A-4 derivative, AC7700. Jpn.
J. Cancer Res. 90:1026-1038, 1999.
Nihei,
Y., Suzuki, M., Okano, A., Tsuji, T., Akiyama, Y., Tsuruo, T., Saito, S., Hori,
K., and Sato, Y. Evaluation of antivascular and antimitoitic effects of tubulin
binding agents to solid tumor therapy. Jpn.
J. Cancer Res. 90:1387-1396, 1999.
Kubota, K., Tada, M., Yamada, S., Hori, K., Saito, S.,
Iwata, R., Sato, K., Fukuda, H., and Ido, T. Comparison of the distribution of
fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue. Eur. J. Nucl.
Med. 26:750-757, 1999.
Yamamoto, H., Atsuchi, N., Tanaka, H., Ogawa, W.,
Abe, M., Takeshita, A., and Ueno, H. Separate roles for H-Ras and Rac in
signaling by transforming growth factor (TGF)-b. H-Ras is essential for activation of MAP kinase, partially required for
transcriptional activation by TGF-b, but not required for signaling of growth suppression by TGF-b. Eur. J. Biochem. 264:110-119, 1999.
2000N
Namba,
K., Abe, M., Saito, S., Satake, M., Ohmoto, T., Watanabe, T, and Sato, Y.
Indispensable role of the transcription factor PEBP2/CBF in angiogenic activity
of a murine endothelial cell MSS31. Oncogene
19:173-179, 2000.
Hori,
K., Saito, S., Takahashi, H., Sato, H., Maeda, H., Sato, Y. Tumor-selective
blood flow decrease induced by an angiotensin converting enzyme inhibitor,
temocapril hydrochloride. Jpn. J. Cancer Res. 91: 261-269, 2000.
Sato,
Y. Molecular mechanism of angiogenesis: Role of Ets-1 in angiogenesis. in gNew
Frontier in Vascular Biology; Thrombosis and hemostasish Eibun Press, Ltd.
pp.1-6, 2000.
Tanaka,
M., Narumi, K., Isemura, M., Abe, M., Sato, Y., Abe, T., Saijo, Y., Nukiwa, T.,
and Satoh, K. Expression of the 37-kDa laminin binding protein in murine lung
tumor cell correlates with tumor angiogenesis. Cancer Lett. 153:161-168, 2000.
Kanno,
S., Oda, N., Abe. M., Terai, Y., Ito, M., Shitara, K., Tabayashi, K., Shibuya,
M., and Sato, Y. Roles of two VEGF receptors, Flt-1 and KDR, in the
signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 19:2138-2146, 2000.
Sato,
Y., Kanno, S., Oda, N., Abe. M., Ito, M., Shitara, K., and Shibuya, M.
Properties of two VEGF receptors, Flt-1 and KDR, in the signal transduction. Ann. N. Y. Acad. Sci. 901:201-207, 2000.
Nakano, T., Abe, M., Tanaka, K., Shineha, R.,
Satomi, S., and Sato, Y. Angiogenesis Inhibition by Transdominant Mutant Ets-1.
J. Cell. Physiol. 184:255-262,
2000.
Sato,
Y. Molecular mechanism of angiogenesis: transcription factors and their
therapeutic relevance. Pharmacol.
Ther. 87:51-60, 2000.
Sato,
Y., Abe, M., Tanaka, K., Iwasaka , C., Oda, N., Kanno, S., Oikawa, M., Nakano,
T., and Igarashi T. Signal transduction and transcriptional regulation of
angiogenesis. Adv. Exp. Med. Biol.
476:109-115, 2000.
2001N
Sato
Y. Role of ETS family transcription
factors in vascular development and angiogenesis. Cell Struct. Funct. 26: 19-24, 2001.
Yashima,
R., Abe, M., Tanaka, K., Ueno, H., Shitara, K., Takenoshita, S., and Sato, Y
Heterogeneity of the signal transduction pathways for VEGF-induced MAPKs
activation in human vascular endothelial cells. J. Cell. Physiol. 188:201-210, 2001.
Teruyama, K., Abe, M., Iwasaka-Yagi, C. Nakano, T.,
Takahashi, S., Yamada, S., and Sato, Y.
Role
of transcription factor Ets-1 in the apoptosis of human vascular endothelial
cells. J.
Cell. Physiol. 188:243-252,
2001.
Iwasaka-Yagi, C., Abe, M., and Sato, Y. TGF-b attenuates the transactivation activity of Ets-1
despite its induction via the inhibition of DNA binding. Tohoku J. Exp. Med. 193: 311-318,
2001.
Terai,
Y., Abe, M., Miyamoto, K., Koike, M., Yamasaki, M., Ueda, M., Ueki, M., Sato,
Y. Vascular smooth muscle cell growth-promoting factor/F-spondin inhibits
angiogenesis via the blockade of integrin avb3 on vascular
endothelial cells. J. Cell. Physiol. 88:394-402, 2001.
Igarashi, T., Abe, M., Oikawa, M., Nukiwa, T., and Sato,
Y. Retinoic
Acids Repress the Expression of ETS-1. Tohoku J. Exp. Med. 194: 35-43, 2001.
Teruyama, K., Abe, M., Nakano, T., Takahashi, S.,
Yamada, S., and Sato, Y. Neuropilin-1 is a downstream target of
transcription factor Ets-1 in human umbilical vein endothelial cells. FEBS Lett. 504: 1-4, 2001.
Oikawa,
M., Abe, M., Kurosawa, H., Hida, W., Shirato, K., and Sato, Y. Hypoxia induces
transcription factor ETS-1 via the activity of hypoxia inducible factor-1. Biochem. Biophys. Res. Commun.
289:39-43, 2001.
Sato, Y., Teruyama,
K., Nakano, T., Oda, N., Abe, M., Tanaka, K., and Iwasaka-Yagi, C. Role of
transcription factors in angiogenesis: Ets-1 promotes angiogenesis as well as
endothelial apoptosis. Ann. N. Y. Acad. Sci. 947,
117-123, 2001.
Abe,
M., and Sato, Y. cDNA microarray analysis of the gene expression profile of
VEGF-induced human umbilical vein endothelial cells. Angiogenesis 4: 289-298, 2001.
Hori,
K., Saito, S., Sato, Y., Kubota, K. Stoppage of blood flow in 3-methyl-
cholanthrene-induced autochthonous primary tumor due to a novel combretastatin
A-4 derivative, AC7700, and its antitumor effect. Med. Sci. Monit. 7: 26-33, 2001.
2002N
Abe, M., Inoue, D., Matsunaga, K., Ohizumi, Y.,
Ueda, H., Asano, T., Murakami, M., and Sato, Y. Goniodomin A, an antifungal polyether macrolide, exhibits
antiangiogenic activities via inhibiting actin reorganization of endothelial
cells. J.
Cell. Physiol. 190: 109-116, 2002.
Miyashita,
H., Yamazaki, T., Akada, T., Niizeki, O., Ogawa, M., Nishikawa, S-I., and Sato,
Y. A mouse orthologue of puromycin insensitive leucyl-specific aminopeptidase
(PILSAP) is expressed in endothelial cells and plays an important role in
angiogenesis. Blood 99:
3241-3249, 2002.
Abe,
M., Oda, N., Shibata, K., Yamasaki, M., and Sato, Y. Augmented binding and
activation of latent transforming growth factor-b by a tryptic fragment
of latency associated peptide. Endothelium
9: 25-36, 2002.
Akada,
K, Yamazaki, T., Miyashita, H., Niizeki, O., Abe, M., Sato, A., Satomi, S., and Sato, Y. Puromycin insensitive leucyl-specific aminopeptidase
(PILSAP) is involved in the activation of endothelial integrins. J. Cell. Physiol. 193: 253-262, 2002.
Hori K, Saito S, Kubota K. A novel combretastatin
A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth
of tumours developing in various tissues and organs. Br. J. Cancer. 86:1604-1614,
2002.
2003N
Sato, Y. The ETS family of transcription factors.
In gGenetics of Angiogenesish (BIOS Scientific Publisher Ltd.
Nakagawa,
T., Abe, M., Yamazaki, T., Miyashita, H., Niwa, H., Kokubun S., and Sato, Y.
HEX acts as a negative regulator of angiogenesis by modulating the expression
of angiogenesis-related gene in endothelial cells in vitro. Arterioscler.
Thromb. Vasc. Biol. 23: 231-237, 2003.
Hori,
K., Saito, S., Sato, Y.,
Sato,
Y. Neovascularization; its molecular mechanism and biology. Intern. Med.
42:295-297, 2003.
Sato,
Y. Molecular diagnosis of tunmor angiogenesis and anti-angiogenic cancer
therapy. Int. J. Clin. Oncol. 8:200-206, 2003.
Sato,
Y. Aminopeptidase and angiogenesis. Endothelium 10: 287-290, 2003.
Hori, K., Saito, S. Microvascular mechanisms by
which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood
flow stasis. Br.
J. Cancer 89:1334-1344, 2003.
2004N
Hori, K., Saito, S. Induction of tumour blood flow
stasis and necrosis a new function for epinephrine similar to that of
combretastatin A-4 derivative AVE8062 (AC7700). Br. J. Cancer 90:549-553,
2004.
Hasegawa,
Y., Abe, M., Shiiba, K., Sasaki, I, and Sato, Y. Transcriptional regulation of
humen angiopoietin-2 by transcription factor ETS-1. Biochem. Biophys. Res.
Commun. 361: 52-58, 2004.
Niizeki,
O., Miyashita, H., Yamasaki, T., Akada, T., Abe, M., Yoshida, N., Toshio
Watanabe, Yoshimatsu, H., and Sato, Y. Transcriptional
regulation of angiogenesis-related puromycin-insensitive leucyl-specific
aminopeptidase in endothelial cells. Arch. Biochem. Biophys. 424: 63-71,
2004.
Watanabe,
D., Takagi, H., Suzuma, K., Suzuma,
Miyashita,
H., Kanemura, M., Yamazaki, T., Abe, M., and Sato, Y. Vascular endothelial zinc finger 1 (Vezf1), an endothelium-specific
transcription factor, plays an important role in angiogenesis: possible
contribution of stathmin/OP18 as a downstream target gene. Arterioscler.
Thromb. Vasc. Biol. 24: 878-884, 2004.
Sato, Y. Role of aminopeptidase in angiogenesis.
Biol. Pharm. Bull. 27: 772-776, 2004.
Hashiya, N., Jo, N., Aoki, M., Matsumoto, K.,
Nakamura, T., Sato, Y., Ogata, N., Ogihara, T., Kaneda, Y., Morishita, R. In vivo
evidence of angiogenesis induced by transcription factor Ets-1. Ets-1 is located
upstream of angiogenesis cascade. Circulation 109:3035-3041, 2004.
Iizuka,
M., Abe, M., Shiiba, K., Sasaki, I, and
Sato,
Y. Down syndrome candidate region 1 (DSCR1), a downstream target of
VEGF in endothelial cells, regulates cell migration and angiogenesis via the
functional interaction with integrin avb3. J. Vasc. Res. 41:334-344, 2004.
Yamazaki, T., Akada, T., Niizeki, O., Suzuki,
T., Miyashita, H., and Sato, Y. Puromycin insensitive leucyl-specific aminopeptidase
(PILSAP) binds and catalyses PDK1, allowing VEGF-stimulated activation of S6K
for endothelial cell proliferation and angiogenesis. Blood 104:2345-2352, 2004.
Watanabe,
K., Hasegawa Y., Yamashita, H.,
Tanaka, H., Terada, Y., Kobayashi, T., Okado, T.,
Inoshita, S., Kuwahara, M., Seth, A., Sato, Y., and Sasaki, S. Expression and
function of Ets-1 during experimental acute renal failure in rats. J. Am. Soc.
Nephrol. 15:3083-3092, 2004.
Hori, K., Saito, S., and Tamai, M. Effect of
irradiation on neovascularization in rat skinfold chambers: Implications for
clinical trials of low-dose radiotherapy for wet-type age-related macular
degeneration. Int.
J. Radiat. Oncol. Biol. Phys. 60:1564-1571, 2004.
Kanemura,
M., Abe, M., Ueda, M., Ueki, M., Awaya, A., and Sato, Y. MS-818 accelerates
mobilization of endothelial progenitor cells and differentiation to endothelial
cells. Endothelium 11: 221-230, 2004.
2005N
Sato,
Y. Gene regulation of a novel angiogenesis inhibitor, vasohibin, in
endothelial cells. Biochem. Biophys. Res. Commun. 327: 700-7006,
2005.
Sato, Y. Angiogenesis and its relevance to tumor biology. In gRecent
Research Advances in
Cancerh
(Research Signpost) pp. 13-21, 2005.
Cho, Y.-J., Abe, M., Kim, S. Y., and Sato, Y. Raf-1 is a binding partner of DSCR1. Arch. Biochem. Biophys. 439: 121-128, 2005.
Miyashita, H.,
and Sato, Y. Metallothionein1 is a
downstream target of VEZF1 in endothelial cells and participates in the
regulation of angiogenesis. Endothelium 12: 163-170, 2005.
Hori, K. Antineoplastic strategy:
irreversible tumor blood flow stasis induced by the combretastatin A-4
derivative AVE8062 (AC7700). Chemotherapy 51: 357-360, 2005.
2006N
Shen, JK., Yang, XR., Sato, Y., and Campochiaro, PA.
Vasohibin
is Up-regulated by VEGF in the Retina and Suppresses VEGF receptor 2 and
Retinal Neovascularization. FASEB J. 20: 723-725, 2006.
Shibuya,
T., Watanabe, K., Yamashita, H.,
Sonoda,
H., Ohta, H., Watanabe, K., Yamashita, H., Kimura H., and Sato, Y. Multiple
processing forms and their biological activities of a novel angiogenesis
inhibitor vasohibin. Biochem. Biophys. Res. Commun.
342: 640-646, 2006.
Sato
Y.: Update on endogenous inhibitors of angiogenesis. Endothelium
13: 147-155, 2006.
Yamashita, H., Abe, M., Watanabe, K.,
Koizumi, T., Abe, M., Yamakuni, T., Ohizumi,
Y., Hitotsuyanagi, Y., Takeya, K., and Sato, Y. Metronomic scheduling of a
cyclic hexapeptide RA-VII for anti-angiogenesis, tumor vessel maturation, and
anti-tumor activity. Cancer Sci. 97: 665-674, 2006.
Abe M., and Sato, Y. Puromycin insensitive leucyl-specific
aminopeptidase (PILSAP) is required for the development of vascular as well as
hematopoietic system in embryoid bodies. Genes Cells 11:719-729, 2006.
Mizui,
M., Isaka, Y., Takabatake, Y., Sato, Y., Kawachi, H.,
Nagasaka, M.,
Kohzuki, M.,
Fujii, T.,
Kanno, S.,
Kawamura, T.,
Onodera, H.,
Itoyama, Y.,
Ichie, M.,
Sato, Y.
Effect of low-voltage electrical stimulation on angiogenic growth factors in
ischaemic rat skeletal muscle. Clin. Exp.
Pharmacol. Physiol. .33: 623-627, 2006.
Sato,
Y. An endothelium-derived angiogenesis inhibitor vasohibin and its significance
in tumor angiogenesis. Cancer Chemother. Pharmacol. Suppl 7: 69-72, 2006.
Kim, Y.S., Lee, H.J., Cho, K.O., Kim, S.Y., Sato, Y., and Cho, Y.J.
Down Syndrome Candidate Region 1 increases protein stability of IΘBΏ: Implication for its anti-inflammatory
effects. J. Biol. Chem. 281: 39051-39061, 2006.
Candi E, Terrinoni A, Rufini A, Chikh A,
Lena AM, Suzuki Y, Sayan BS, Knight RA, Melino G. p63 is upstream of IKK alpha
in epidermal development. J. Cell Sci. 119: 4617-4622 ,2006.
Kobayashi M,
Nishita M, Mishima T, Ohashi K, Mizuno K. MAPKAPK-2-mediated
LIM-kinase activation is critical for VEGF-induced actin remodeling and cell
migration. EMBO J. 25: 713-726, 2006.
2007N
Sato, Y., and
Sonoda, H. The vasohibin family: a negative regulatory system of angiogenesis
genetically programmed in endothelial cells. Arterioscler. Thromb. Vasc. Biol.
27: 37-41, 2007.
Saito,
A., Sugawara, A., Uruno, A., Kudo, M., Kagechika, H., Sato, Y., Owada, Y.,
Kondo, H., Sato, M., Kurabayashi, M., Imaizumi, M., Tsuchiya, S., and Ito, S. All-trans
retinoic acid induces in vitro angiogenesis via retinoic acid receptor:
Possible involvement of paracrine effects of endogenous vascular endothelial growth
factor signaling. Endocrinology 148: 1412-1423, 2007.
Suzuki, T., Abe,
M., Miyashita, H., Kobayashi, T., and Sato, Y. Puromycin insensitive
leucyl-specific aminopeptidase (PILSAP) affects RhoA activation in endothelial
cells. J. Cell. Physiol. 211: 708-715, 2007.
Sato, Y. Endogenous inhibitors of angiogenesis. Angiogenesis. In gBasic Science and Clinical Applicationsh (Transworld Research Network) pp 1-14, 2007.
2008N
Sato, Y. VEGFR1
for lymphangiogenesis: an alternative signaling pathway? Arterioscler. Thromb.
Vasc. Biol. 28: 604-605, 2008.
Yoshinaga, K.,
Moriya, T., Nagase, S., Takano, T., Niikura, H., Ito, K., Nobuo Yaegashi, N.,
and Sato, Y. Vasohibin, a novel endothelium-derived angiogenesis inhibitor: its
expression on endometrial carcinoma in relation to tumor vascularity. Cancer Sci.
99: 914-919, 2008.
Wakusawa,
R., Abe, T., Sato, H., Yoshida, M., Kunitaka, H., Sato, Y., and Nishida K.
Expression of vasohibin, an antiangiogenic factor, in human choroidal
neovascular membranes. Am. J. Ophthalmol. 146:235-243, 2008.
Hori, K., Furumoto,
S., and Kubota, K. Tumor blood flow interruption after radiotherapy
strongly inhibits tumor regrowth. Cancer Sci. 99:1485-1491, 2008.
2009N
Lefter LP, Dima S,
Sunamura M, Furukawa T, Sato Y, Abe M, Chivu M, Popescu I, and Horii A.
Transcriptional silencing of ETS-1 efficiently suppresses angiogenesis of
pancreatic cancer. Cancer Gene Ther. 16:137-148, 2009.
Nishida Y, Shibata K, Yamasaki M, Sato Y, and Abe M. A
possible role of vimentin on the cell surface for the activation of latent transforming
growth factor-b. FEBS Lett. 583: 308–312, 2009.
Naito H, Kidoya
H, Sato Y, and Takakura N. Induction and expression of anti-angiogenic
vasohibins in the hematopoietic stem/progenitor cell population. J. Biochem. 145:
653-659, 2009.
Kimura H, Miyashita H,
Suzuki Y, Kobayashi M, Watanabe K, Sonoda H, Ohta H, Fujiwara T, Shimosegawa T
and Sato Y. Distinctive localization and opposed roles of vasohibin-1 and
vasohibin-2 in the regulation of angiogenesis. Blood 113: 4810-4818, 2009.
Hosaka T, Kimura H, Heishi T, Suzuki Y, Miyashita H, Ohta H,
Sonoda H, Moriya T, Suzuki S, Kondo T, Sato Y. Vasohibin-1 expressed in
endothelium of tumor vessels regulates angiogenesis. Am. J. Pathol. 175: 430-439, 2009.
Taniguchi K,
Sasaki K, Watari K, Yasukawa H, Imaizumi T, Ayada T, Okamoto F, Ishizaki
T, Kato R, Kohno R, Kimura H, Sato Y, Ono M, Yonemitsu Y, Yoshimura A. Suppression
of Sproutys has a therapeutic effect for a mouse model of ischemia by
enhancing angiogenesis. PLoS ONE. 4:e5467, 2009.
Nasu
T, Maeshima Y, Kinomura M, Hirokoshi-Kawahara K, Tanabe K, Sugiyama H, Sonoda
H, Sato Y, Makino H. Vasohibin-1, a
negative feedback regulator of angiogenesis, ameliorates renal alterations in a
mouse model of diabetic nephropathy. Diabetes 58: 2365-2375, 2009.
Lee HJ, Kim YS, Sato
Y, Cho Y-J. RCAN1-4 knockdown
attenuates cell growth through the inhibition of Ras signaling. FEBS Lett. 583: 2557-64, 2009.
Suzuki H, Ohkuchi
A, Matsubara S, Takei Y, Murakami M, Shibuya M, Suzuki M, Sato Y. The effect of
recombinant PlGF-2 on hypertension induced by full-length mouse sFlt-1
adenoviral vector in pregnant mice. Hypertension 54: 1129-1135, 2009.
Miyake K, Nishida
K, Kadota Y, Yamasaki H, Nasu T, Saitou D, Tanabe K, Sonoda H, Sato Y, Maeshima Y, Makino H. Inflammatory Cytokine-induced
Expression of Vasohibin-1 by Rheumatoid
Synovial Fibroblasts. Acta Medica Okayama 2009 (in press).
Sato, Y. Delta-like 4 and vasohibin 1: two
endothelium-produced negative regulators of angiogenesis with distinctive
roles. Eur. Cytokine Netw. 20, 1-5, 2009.
2010N
Komi Y, Sogabe
Y, Ishibashi N, Sato Y, Moriwaki H, Shimokado K, Kojima S. Acyclic retinoid inhibits angiogenesis via
suppressing MAPK pathway. Lab. Invest. 90: 52-60, 2010.
Miura S, Mitsui
K, Heishi T, Shukunami C, Sekiguchi K, Kondo J, Sato Y, Hiraki Y. Impairment of
VEGF-A-stimulated lamellipodial extensions and motility of vascular endothelial
cells by Chondromodulin-I, a cartilage-derived angiogenesis inhibitor. Exp.
Cell Res. 316: 775-788 2010.
Sato, Y. The vasohibin
family. Pharmaceuticals 3, 433-440, 2010.
Heishi T, Hosaka T,
Suzuki Y, Miyashita H, Oike Y, Takahashi T, Nakamura T, Arioka S, Mitsuda Y,
Takakura T, Hojo K, Matsumoto M, Yamauchi C, Ohta H, Sonoda H, Sato Y. Endogenous
angiogenesis inhibitor vasohibin1 exhibits a broad-spectrum anti-lymphangiogenic
activity and suppresses lymph node metastasis. Am. J. Pathol. (Epub ahead of print).
Tamaki K,
Sasano H, Maruo Y, Takahashi Y, Miyashita M, Moriya T, Sato Y, Hirakawa H,
Tamaki N, Watanabe M, Ishida T, Ohuchi N. Vasohibin-1 as a potential predictor
of aggressive behavior of ductal carcinoma in situ of the breast. Cancer Sci.
2010 (Epub
ahead of print).
Yoshida T,
Sato Y, Morita I, Abe M. Pigpen, a nuclear coiled body component protein is
involved in angiogenesis. Cancer Sci. 2010 (Epub ahead of print).